Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced on May, 19 2026 that its controlling shareholder, Tianjin Pharmaceutical Holdings Co., Ltd. (TPH), has been informed of a proposed transfer of 100% of the equity in Shanghai Liuliguang Medical Development Co., Ltd.

\n\n

SIIC Shanghai (Holdings) Co., Ltd. and Shanghai SIIC Investment Development Co., Ltd. intend to sell their entire stakes in Liuliguang Medical through a public tender on the Shanghai United Assets and Equity Exchange. The pre-disclosure period for the tender runs from May, 19 2026 to Jun, 16 2026.

\n\n

Liuliguang Medical holds 35% of Jinhushen Biological Medical Science and Technology Co., Ltd., which owns 67% of TPH. TPH directly controls approximately 43.008% of Tianjin Pharmaceutical Da Ren Tang Group’s issued share capital. The tender details have been posted on the exchange’s website.